search
Back to results

Adherence and Preference of Continuous Positive Airway Pressure Versus Mandibular Advancement Splints in Obstructive Sleep Apnea Patients: A Randomized Trial (CHOICE)

Primary Purpose

Obstructive Sleep Apnea

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Positive Airway Pressure (PAP)
Mandibular Advancement Splints (MAS)
Sponsored by
University of British Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obstructive Sleep Apnea focused on measuring Adherence, CPAP, Oral Appliance, Mandibular Advancement Splints, Preference

Eligibility Criteria

19 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

You may be able to participate in this study if:

  • You are naïve to treatment (never used CPAP or oral appliance, nor had surgery for sleep apnea);
  • You are between 19-75 years old;
  • You have a Body Mass Index (BMI) ≤ 35;
  • You have enough teeth (at least 8 per arch) for MAS;
  • You have:

    • an Apnea-Hypopnea Index (AHI) within the range 10 ≤ AHI ≤ 50 documented with polysomnography in the last 2 years; ***OR***
    • a Respiratory Disturbance Index (RDI) within the range 20 ≤ RDI ≤ 50 documented with level III portable sleep test; ***OR***
    • an Oxygen Desaturation Index (ODI) ≥ 10; and
  • You have had a sleep test within the past 2 years.

Exclusion Criteria:

You may not be able to participate in this study if:

  • You have extensive periodontal disease with significant tooth mobility (disease around your teeth);
  • You are unable to protrude the jaw (unable to extend your jaw);
  • You have a lack of a sufficient vertical opening to accommodate an appliance;
  • You have uncontrolled congestive heart failure (defined as a prior clinical diagnosis, an ejection cutoff of 40% or a clinical sign in the opinion of a primary care physician or cardiologist) that makes it unsafe for you to participate in the trial in the opinion of the investigators;
  • You have coronary artery disease unless stable for at least 6 months and considered by the investigators to have a stable disease;
  • You have a history of angina (chest pain when your heart does not get enough blood), myocardial infarction (heart attack) or stroke;
  • You have a history of major depressive disorder (such as bipolar disorder) along with current moderate or severe disease;
  • You have cancer unless in remission (decreasing signs of your cancer being present) for more than 1 year;
  • You have known renal (kidney) failure with need for dialysis;
  • You are pregnant (if a female participant becomes pregnant during the trial, she will be withdrawn from the study);
  • You have had a near miss or prior automobile accident due to sleepiness within the past 12 months; and/or
  • At nighttime, 30% of the night is at ≤ 90% oxygen saturation levels.

Sites / Locations

  • University of British Columbia
  • University of Montreal / Université de Montréal
  • Laval University / Université Laval

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

MAS-PAP

PAP-MAS

Arm Description

Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)

Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)

Outcomes

Primary Outcome Measures

Objectively measured adherence (hours/night and nights/week of intervention use).
Measuring objective adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.
Objectively measured adherence (hours/night and nights/week of intervention use).
Measuring changes in objectively measured adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.
Objectively measured adherence (hours/night and nights/week of intervention use).
Measuring changes in objectively measured adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.
Objectively measured adherence (hours/night and nights/week of intervention use).
Measuring changes in objectively measured adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.

Secondary Outcome Measures

Apnea-hypopnea index
Measuring apnea-hypopnea index (events/hour of sleep from Stardust-Phillips Respironics) to measure intervention efficacy (e.g. AHI)
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Measuring Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Epworth Sleepiness Scale (ESS) questionnaire responses.
Measuring responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness.
Chalder fatigue scale questionnaire responses
Measuring responses to the Chalder fatigue scale which assesses fatigue in the present state.
SF-36 survey responses
Measuring SF-36 survey responses which assesses general health status.
Apnea-hypopnea index
Measuring changes in apnea-hypopnea index (events/hour of sleep from Stardust-Phillips Respironics) to measure intervention efficacy (e.g. AHI)
Apnea-hypopnea index
Measuring changes in apnea-hypopnea index (events/hour of sleep from Stardust-Phillips Respironics) to measure intervention efficacy (e.g. AHI)
Functional Outcomes of Sleep Questionnaire (FOSQ) responses.
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Functional Outcomes of Sleep Questionnaire (FOSQ) responses.
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Functional Outcomes of Sleep Questionnaire (FOSQ) responses.
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Epworth Sleepiness Scale (ESS) questionnaire responses.
Measuring changes in Epworth Sleepiness Scale (ESS) Questionnaire responses to compare daytime sleepiness.
Epworth Sleepiness Scale (ESS) questionnaire responses.
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness
Epworth Sleepiness Scale (ESS) questionnaire responses
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness.
Epworth Sleepiness Scale (ESS) questionnaire responses.
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness.
Chalder fatigue scale questionnaire responses
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
Chalder fatigue scale questionnaire responses
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
Chalder fatigue scale questionnaire responses
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
Chalder fatigue scale questionnaire responses
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
SF-36 survey responses.
Measuring changes in SF-36 survey responses which assesses general health status.
SF-36 survey responses.
Measuring changes in SF-36 survey responses which assesses general health status.
SF-36 survey responses.
Measuring changes in SF-36 survey responses which assesses general health status.
SF-36 survey responses.
Measuring changes in SF-36 survey responses which assesses general health status.

Full Information

First Posted
August 29, 2014
Last Updated
November 24, 2022
Sponsor
University of British Columbia
Collaborators
Université de Montréal, Laval University
search

1. Study Identification

Unique Protocol Identification Number
NCT02242617
Brief Title
Adherence and Preference of Continuous Positive Airway Pressure Versus Mandibular Advancement Splints in Obstructive Sleep Apnea Patients: A Randomized Trial
Acronym
CHOICE
Official Title
Adherence and Preference of Continuous Positive Airway Pressure Versus Mandibular Advancement Splints in Obstructive Sleep Apnea Patients: A Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
November 2015 (Actual)
Primary Completion Date
June 2020 (Actual)
Study Completion Date
June 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of British Columbia
Collaborators
Université de Montréal, Laval University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obstructive sleep apnea (OSA) is a major health problem affecting over 1,000,000 Canadians. It is the cause of significant healthcare costs with increased morbidity and mortality. The two most common and effective therapies used to treat OSA are: (1) Continuous or Automatic Positive Airway Pressure (PAP), and (2) Mandibular Advancement Splints (MAS). While both therapies reduce upper airway collapse during sleep, they differ in efficacy, acceptance, cost and side-effects, but surprisingly are similar in improving quality of life, sleepiness and blood pressure. PAP is more effective in reducing apneas while MAS is easier to use. Until now, studies have used self-reported adherence data on MAS versus objective adherence on PAP. Many studies have hypothesized that the sub-optimal efficacy with MAS therapy is counterbalanced by the superior adherence relative to PAP, resulting in a similar effectiveness for both treatments. Compliance smart chips are a recent innovation for MAS and could be used to prove this hypothesis and allow a new and complete comparison of effectiveness (efficacy + adherence) between MAS and PAP. Understanding the patient's objective adherence and long-term symptomatic improvement would provide vital information to doctors and dentists in choosing the right treatment for patients. Sixty OSA patients will receive both PAP and MAS in a random sequence. This innovative study lead by two experienced new investigators, and a research team of multidisciplinary experts, will assess objective adherence, treatment efficacy, patient preference, sleepiness and quality of life of each treatment used at home for 1 month per treatment. After this, patients will be able to go back and forth between both treatments during an additional 6-month period. The results of this study will be used by healthcare policy makers as well as clinicians who need to be part of the treatment plan decision for the many Canadians who suffer from sleep apnea.
Detailed Description
The primary aim of this study is to assess objective adherence to treatment, for PAP and MAS, and to evaluate if there will be similar effectiveness (efficacy+adherence) between PAP and MAS treatment for patients with mild to severe OSA. The secondary aim is to assess if patient preference does correlate to the final treatment adherence. An exploratory aim is to assess if the strategy of patients having both treatments available to use interchangeably could further improve treatment adherence, sleepiness, quality of life and fatigue. Having a better insight into patient adherence will improve the cost-effectiveness of treatment and will improve the health and quality of life for many Canadians who suffer from sleep apnea. The proposed trial is a randomized open-label, two-treatment, two-period cross-over trial followed by an observational trial. Sixty OSA patients (10≤AHI≤50) will receive both PAP and MAS. As a recent innovation, we have adherence monitors for MAS that can give a new and comprehensive comparative analysis of the effectiveness between MAS and PAP. In the randomized trial phase the two treatments will be used separately for 1 month each (after treatment adaptation/titration of 1-2 months for each device). Treatment efficacy and daily treatment use data will be assessed together with changes in symptoms (quality of life, sleepiness and fatigue). Patient initial preference will be determined by using a patient decision aid. This will be followed by the observational trial phase, where all patients will have access to both interventions at home for 6 months and be allowed to choose on a daily basis the intervention to use. The intervention duration of 6 months is to allow for a sustained response in long-term adherence and to observe changes in quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea
Keywords
Adherence, CPAP, Oral Appliance, Mandibular Advancement Splints, Preference

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
79 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MAS-PAP
Arm Type
Active Comparator
Arm Description
Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
Arm Title
PAP-MAS
Arm Type
Active Comparator
Arm Description
Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
Intervention Type
Device
Intervention Name(s)
Positive Airway Pressure (PAP)
Other Intervention Name(s)
CPAP, auto-CPAP, APAP
Intervention Description
Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
Intervention Type
Device
Intervention Name(s)
Mandibular Advancement Splints (MAS)
Other Intervention Name(s)
Oral appliance, Mandibular advancement devices, Somnodent device
Intervention Description
Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
Primary Outcome Measure Information:
Title
Objectively measured adherence (hours/night and nights/week of intervention use).
Description
Measuring objective adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.
Time Frame
At 1 month in the MAS treatment arm
Title
Objectively measured adherence (hours/night and nights/week of intervention use).
Description
Measuring changes in objectively measured adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.
Time Frame
At 1 month in CPAP treatment arm
Title
Objectively measured adherence (hours/night and nights/week of intervention use).
Description
Measuring changes in objectively measured adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.
Time Frame
At 1 month of using both treatments interchangeably.
Title
Objectively measured adherence (hours/night and nights/week of intervention use).
Description
Measuring changes in objectively measured adherence (hours/night and nights/week of intervention use), indicated by the smart chips and symptoms.
Time Frame
At 6 months of using both treatments interchangeably
Secondary Outcome Measure Information:
Title
Apnea-hypopnea index
Description
Measuring apnea-hypopnea index (events/hour of sleep from Stardust-Phillips Respironics) to measure intervention efficacy (e.g. AHI)
Time Frame
At baseline
Title
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Description
Measuring Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Time Frame
At baseline
Title
Epworth Sleepiness Scale (ESS) questionnaire responses.
Description
Measuring responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness.
Time Frame
At baseline
Title
Chalder fatigue scale questionnaire responses
Description
Measuring responses to the Chalder fatigue scale which assesses fatigue in the present state.
Time Frame
At baseline
Title
SF-36 survey responses
Description
Measuring SF-36 survey responses which assesses general health status.
Time Frame
At baseline
Title
Apnea-hypopnea index
Description
Measuring changes in apnea-hypopnea index (events/hour of sleep from Stardust-Phillips Respironics) to measure intervention efficacy (e.g. AHI)
Time Frame
At 1 month in MAS treatment arm
Title
Apnea-hypopnea index
Description
Measuring changes in apnea-hypopnea index (events/hour of sleep from Stardust-Phillips Respironics) to measure intervention efficacy (e.g. AHI)
Time Frame
At 1 month in CPAP treatment arm
Title
Functional Outcomes of Sleep Questionnaire (FOSQ) responses.
Description
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Time Frame
At 1 month in MAS treatment arm
Title
Functional Outcomes of Sleep Questionnaire (FOSQ) responses.
Description
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Time Frame
At 1 month of using both treatments interchangeably
Title
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Description
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Time Frame
At 6 months of using both treatments interchangeably
Title
Functional Outcomes of Sleep Questionnaire (FOSQ) responses.
Description
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Time Frame
At 1 month in CPAP treatment arm
Title
Epworth Sleepiness Scale (ESS) questionnaire responses.
Description
Measuring changes in Epworth Sleepiness Scale (ESS) Questionnaire responses to compare daytime sleepiness.
Time Frame
At 1 month in MAS treatment arm
Title
Epworth Sleepiness Scale (ESS) questionnaire responses.
Description
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness
Time Frame
At 1 month in CPAP treatment arm.
Title
Epworth Sleepiness Scale (ESS) questionnaire responses
Description
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness.
Time Frame
At 1 month of using both treatments interchangeably
Title
Epworth Sleepiness Scale (ESS) questionnaire responses.
Description
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare daytime sleepiness.
Time Frame
At 6 months of using both treatments interchangeably.
Title
Chalder fatigue scale questionnaire responses
Description
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
Time Frame
At 1 month in MAS treatment arm
Title
Chalder fatigue scale questionnaire responses
Description
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
Time Frame
At 1 month in CPAP treatment arm
Title
Chalder fatigue scale questionnaire responses
Description
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
Time Frame
At 1 month of using both treatments interchangeably
Title
Chalder fatigue scale questionnaire responses
Description
Measuring changes in responses to the Chalder fatigue scale which assesses fatigue in the present state.
Time Frame
At 6 months of using both treatments interchangeably.
Title
SF-36 survey responses.
Description
Measuring changes in SF-36 survey responses which assesses general health status.
Time Frame
At 1 month in MAS treatment arm
Title
SF-36 survey responses.
Description
Measuring changes in SF-36 survey responses which assesses general health status.
Time Frame
At 1 month in CPAP treatment arm.
Title
SF-36 survey responses.
Description
Measuring changes in SF-36 survey responses which assesses general health status.
Time Frame
At 1 month of using both treatments interchangeably.
Title
SF-36 survey responses.
Description
Measuring changes in SF-36 survey responses which assesses general health status.
Time Frame
At 6 months of using both treatments interchangeably.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: You may be able to participate in this study if: You are naïve to treatment (never used CPAP or oral appliance, nor had surgery for sleep apnea); You are between 19-75 years old; You have a Body Mass Index (BMI) ≤ 35; You have enough teeth (at least 8 per arch) for MAS; You have: an Apnea-Hypopnea Index (AHI) within the range 10 ≤ AHI ≤ 50 documented with polysomnography in the last 2 years; ***OR*** a Respiratory Disturbance Index (RDI) within the range 20 ≤ RDI ≤ 50 documented with level III portable sleep test; ***OR*** an Oxygen Desaturation Index (ODI) ≥ 10; and You have had a sleep test within the past 2 years. Exclusion Criteria: You may not be able to participate in this study if: You have extensive periodontal disease with significant tooth mobility (disease around your teeth); You are unable to protrude the jaw (unable to extend your jaw); You have a lack of a sufficient vertical opening to accommodate an appliance; You have uncontrolled congestive heart failure (defined as a prior clinical diagnosis, an ejection cutoff of 40% or a clinical sign in the opinion of a primary care physician or cardiologist) that makes it unsafe for you to participate in the trial in the opinion of the investigators; You have coronary artery disease unless stable for at least 6 months and considered by the investigators to have a stable disease; You have a history of angina (chest pain when your heart does not get enough blood), myocardial infarction (heart attack) or stroke; You have a history of major depressive disorder (such as bipolar disorder) along with current moderate or severe disease; You have cancer unless in remission (decreasing signs of your cancer being present) for more than 1 year; You have known renal (kidney) failure with need for dialysis; You are pregnant (if a female participant becomes pregnant during the trial, she will be withdrawn from the study); You have had a near miss or prior automobile accident due to sleepiness within the past 12 months; and/or At nighttime, 30% of the night is at ≤ 90% oxygen saturation levels.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernanda R Almeida, DDS, MSc, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of British Columbia
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6T 1Z3
Country
Canada
Facility Name
University of Montreal / Université de Montréal
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H3T 1J4
Country
Canada
Facility Name
Laval University / Université Laval
City
Québec
ZIP/Postal Code
G1V 4G5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
23585745
Citation
Almeida FR, Mulgrew A, Ayas N, Tsuda H, Lowe AA, Fox N, Harrison S, Fleetham JA. Mandibular advancement splint as short-term alternative treatment in patients with obstructive sleep apnea already effectively treated with continuous positive airway pressure. J Clin Sleep Med. 2013 Apr 15;9(4):319-24. doi: 10.5664/jcsm.2576.
Results Reference
background
PubMed Identifier
33745505
Citation
Alshhrani WM, Hamoda MM, Okuno K, Kohzuka Y, Fleetham JA, Ayas NT, Comey R, Almeida FR. The efficacy of a titrated tongue-stabilizing device on obstructive sleep apnea: a quasi-experimental study. J Clin Sleep Med. 2021 Aug 1;17(8):1607-1618. doi: 10.5664/jcsm.9260.
Results Reference
derived

Learn more about this trial

Adherence and Preference of Continuous Positive Airway Pressure Versus Mandibular Advancement Splints in Obstructive Sleep Apnea Patients: A Randomized Trial

We'll reach out to this number within 24 hrs